ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2026
Altered Kynurenine Pathway Metabolism in Drug-naive Children and Adolescents with Generalized Anxiety Disorder.
Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Generalized anxiety disorder (GAD) is among the most common psychiatric conditions in children and adolescents. Although its aetiology remains unclear, emerging evidence highlights the role of immune-metabolic pathways in its development. This study aimed to investigate alterations in the kynurenine pathway (KP) metabolites in drug-naive paediatric patients with GAD compared to healthy controls. Methods: Twenty-six drug-naive children with GAD and thirty-two age- and sex-matched healthy controls were enrolled. Serum levels of tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), and quinolinic acid (QUIN) were measured using ELISA. Enzymatic activity indices, including KYN/TRP (IDO/TDO), KYNA/KYN (KAT), and QUIN/KYN (KMO), were calculated. Group differences and correlations with clinical anxiety scores were analysed. Additionally, ROC analysis was performed to evaluate the diagnostic performance of TRP levels in predicting GAD. Results: TRP levels were significantly elevated in the GAD group (median: 62.8 μmol/L) compared to controls (42.9 μmol/L, Conclusion: These findings suggest that disrupted tryptophan metabolism, characterized by reduced KP activation and altered neurotoxic metabolite levels, may contribute to the pathophysiology of paediatric GAD. The KP may represent a promising target for future biomarker and therapeutic research in anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.